Company: SXTPW
Filing Date: 2025-03-27
Form Type: 10-K
Source: 0001013762-25-003343
Chunk: 1448

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-03-27
Form: 10-K
Item: Item 6
Chunk 1448
---
 to purchase one share of the Company’s common stock at an exercise
price of $381.60 per share (a “Non-tradeable Warrant”). The Tradeable Warrants and Non-Tradeable Warrants were immediately
exercisable on the date of issuance and will expire five years from the date of issuance (July 12, 2023 to July 12, 2028).

The Company granted the underwriters a 45-day
over-allotment option to purchase up to 3,538 shares of the Company’s common stock at a price of $316.80 per share and/or 3,538
Tradeable Warrants at a price of $0.60 per Tradeable Warrant and/or 3,538 Non-tradeable Warrants at $0.60 per Non-tradeable Warrant,
or any combination thereof (the “IPO Over-Allotment”). On July 13, 2023, the underwriters partially exercised the Over-Allotment
and purchased an additional 1,678 Tradeable Warrants and 1,678 Non-tradeable Warrants. The Company also issued to the underwriters warrants
to purchase 1,416 shares of the Company’s common stock, at an exercise price of $349.80 per share, equal to 110% of the offering
price per unit (the “IPO Representative Warrants”). The IPO Representative Warrants are exercisable for a period of five
years from the date of issuance (July 14, 2023 to July 14, 2028).

The units were offered and sold pursuant to the
Company’s Registration Statement on Form S-1, as amended (File No. 333-269483), originally filed with the Securities and Exchange
Commission (the “SEC”) on January 31, 2023 (the “IPO Registration Statement”) and the final prospectus filed
with the SEC pursuant to Rule 424(b)(4) of the Securities Act of 1933, as amended. The Registration Statement was declared effective
by the SEC on July 11, 2023. The common stock and tradeable warrants began trading on The Nasdaq Capital Market on July 12, 2023 under
the symbols “SXTP” and “SXTPW,” respectively. The closing of the IPO occurred on July 14, 2023.

Risks and Uncertainties

The Company is subject to risks common to companies
in the biopharmaceutical industry